NDA 212862 · Mylan Ireland LTD
Pretomanid
Pretomanid · Oral · Antimycobacterial
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Nov 22, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Aug 14, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
44
12 Phase 3, 9 recruiting
FAERS reports
760
739 serious, 294 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 15, 2024.
Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] . Limited Population: Pretomanid Tablet is an antimycobacterial indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) that is resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of...
Mechanism: Pretomanid is a nitroimidazooxazine antimycobacterial drug [see Microbiology (12.4) ] . Mechanism of Action Pretomanid Tablet is a nitroimidazooxazine antimycobacterial drug. Pretomanid kills actively replicating M. tuberculosis by inhibiting mycolic acid biosynthesis, thereby blocking cell wall production. Under anaerobic conditions, against non-replicating bacteria, pretomanid acts as a respiratory poison following nitric oxide release. All of these activities require nitro-reduction of pretomanid within the mycobacterial cell by the deazaflavin-dependent nitroreductase, Ddn, which is...
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 22, 2024 Supplement 8 · Efficacy OrphanLabelMedication GuideLetter
- Aug 14, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- PRETOMANID · PRETOMANID 200MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pretomanid" as an intervention, any sponsor and status, largest first.
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06114628 · 2,500 participants (planned) · Start Jan 9, 2024 · Primary completion Feb 24, 2027
Drug: Ganfeborole; BTZ-043 and 11 more · For: Pulmonary Tuberculosis
Sites: Chisinau, Moldova; Cape Town, South Africa; George, South Africa · 11 sites in all
- A PAN-USR TB Multi-Center TrialPivotal-lookingRecruiting
Shenzhen Third People's HospitalAcademic, hospital or other
NCT06905522 · 610 participants (planned) · Start Jun 18, 2025 · Primary completion Jan 2029
Drug: Bedaquiline (B); Sitafloxacin (S) and 7 more · For: Pulmonary Tuberculosis
Sites: Beijing, China; Shenzhen, China; Ürümqi, China
- Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)Pivotal-lookingCompleted
Medecins Sans Frontieres, NetherlandsAcademic, hospital or other
NCT02589782 · 552 participants · Start Jan 2017 · Primary completion Aug 5, 2022
Drug: Bedaquiline; Pretomanid and 4 more · For: Tuberculosis, Multidrug-Resistant; Extensively Drug-Resistant Tuberculosis; Tuberculosis, Pulmonary
Sites: Minsk, Belarus; Johannesburg, South Africa; Durban, South Africa · 7 sites in all
- A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07209761 · 532 participants (planned) · Start Oct 16, 2025 · Primary completion Sep 29, 2028
Drug: Bedaquiline; Quabodepistat and 3 more · For: Rifampicin-Resistant Pulmonary Tuberculosis; Multidrug-Resistant Pulmonary Tuberculosis
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 42 sites in all
- Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult PatientsPivotal-lookingCompleted
Global Alliance for TB Drug DevelopmentAcademic, hospital or other
NCT03338621 · 455 participants · Start Jul 30, 2018 · Primary completion Jul 1, 2021
Drug: Pretomanid; Bedaquiline and 4 more · For: Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR and 2 more
Sites: Rio de Janeiro, Brazil; Tbilisi, Georgia; Kuala Lumpur, Malaysia · 26 sites in all
- Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in IndiaPivotal-lookingStatus unknown
Tuberculosis Research Centre, IndiaGovernment (non-federal)
NCT05040126 · 400 participants (planned) · Start Oct 7, 2021 · Primary completion Dec 31, 2024
Drug: Linezolid; Bedaquiline and 1 more · For: Pre-Extensively Drug-Resistant Pulmonary TB; Treatment Intolerant Multidrug-Resistant Pulmonary TB; Non-responsive Multidrug-Resistant Pulmonary TB
Sites: Agra, India
- Program for Rifampicin-Resistant Disease With Stratified Medicine for TuberculosisPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06441006 · 400 participants (planned) · Start Oct 3, 2025 · Primary completion Aug 2031
Drug: Bedaquiline; Linezolid and 3 more · For: Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR
Sites: Ulaanbaatar, Mongolia; Kotri, Pakistan; Lima, Peru · 6 sites in all
- PanACEA - STEP2C -01Pivotal-lookingRecruiting
Michael HoelscherAcademic, hospital or other
NCT05807399 · 390 participants (planned) · Start Apr 14, 2023 · Primary completion Oct 31, 2027
Drug: BTZ-043; Rifampicin and 9 more · For: Pulmonary Tuberculosis; Other Specified Pulmonary Tuberculosis
Sites: Lambaréné, Gabon; Blantyre, Malawi; Maputo, Mozambique · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death126
- anaemia84
- neuropathy peripheral81
- off label use68
- nausea57
- electrocardiogram qt prolonged53
- decreased appetite28
- acute kidney injury27
- toxicity to various agents26
- alanine aminotransferase increased23
- aspartate aminotransferase increased22
- hepatotoxicity22
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 3 |
| 2018 | 4 |
| 2019 | 13 |
| 2020 | 9 |
| 2021 | 4 |
| 2022 | 69 |
| 2023 | 126 |
| 2024 | 173 |
| 2025 | 192 |
| 2026 | 165 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pretomanid (Pretomanid)
2024 spending
$55K
Beneficiaries
21
70 claims
Per beneficiary
$2,596
$22.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,862 |
| 2021 | $30,315 |
| 2022 | $39,555 |
| 2023 | $55,772 |
| 2024 | $54,520 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Conradie F, Diacon AH, Ngubane N, et al. · N Engl J Med 2020 · Clinical Trial, Research Support, Non-U.S. Gov't
- Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F, Bagdasaryan TR, Borisov S, et al. · N Engl J Med 2022 · Randomized Controlled Trial
- A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, et al. · N Engl J Med 2022 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review.
Silva DR, Fernandes FF, Ferreira JC, et al. · J Bras Pneumol 2025 · Systematic Review
- Pretomanid for tuberculosis: a systematic review.
Gils T, Lynen L, de Jong BC, et al. · Clin Microbiol Infect 2022 · Systematic Review
- Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial.
Padmapriyadarsini C, Oswal VS, Jain CD, et al. · Clin Infect Dis 2024 · Randomized Controlled Trial, Multicenter Study
Sponsor: Mylan Ireland LTD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.